Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Chloroquine as a Novel Therapeutic Strategy in Breast Cancer

NCT02333890 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT02333890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02333890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Chloroquine as a Novel Therapeutic Strategy in Breast Cancer
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 2
Overall status
Unknown status
Start date
July 31, 2015
Completion date
March 31, 2018
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, invasive breast cancer